EUVIMEDEUVIMED entdecken
Open Access

Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine

Kayla E Cooper, Khadijah E Abdallah, Rebekah S M Angove, Kathleen D Gallagher, Vence L Bonham

Ethnicity & Disease · 20.01.2022 · 32 (1) · 39-48

DOI: 10.18865/ed.32.1.39 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ethnicity & Disease, online erschienen am 20.01.2022. Verfasst von Kayla E Cooper und 4 weiteren Autor:innen. Beteiligte Einrichtung: Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine. Die Arbeit wurde bisher 21-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Precision medicine is revolu­tionizing cancer treatment. However, there has been limited investigation of barriers patients endure to access precision cancer medicine. This study aims to report the experiences of underserved patient popula­tions with limited access to genomic testing, clinical trials, and precision cancer treat­ment.

Methods

A mixed-method study was employed to quantitatively evaluate patients (N=300) seeking precision cancer medi­cine between January 2014- August 2017. Qualitatively, we conducted semi-structured interviews with eight case managers who navigate the health care and health insur­ance systems to provide patients with access to precision cancer medicine care. All inter­views were analyzed to identify themes.

Results

Within our patient cohort, 69% were diagnosed in stage I of cancer disease. Overall, 27 patients (9%) were denied treat­ment as a final outcome of their case due to insurance denials, 35 patients (12%) died before gaining access to precision cancer medicine, and 6 patients (2%) received precision cancer medicine through clinical trials. Four broad thematic areas emerged from the qualitative analysis: 1) lack of patient, provider and insurer knowledge of precision cancer medicine; 2) barriers to clinical trial participation; 3) lack of patient health literacy; and 4) barriers to timely access to care.

Conclusion

Our combined analyses sug­gest that both system-level and patient-level barriers limit patient access to precision cancer medicine options. Additionally, we found that these barriers may exist not only for traditionally underserved patients, but also for resourced and insured patients trying to access precision cancer medicine. Ethn Dis. 2022;32(1):39-48; doi:10.18865/ed.32.1.39

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPrecision MedicineHealth Services AccessibilityHumansMedically Underserved AreaQualitative ResearchVulnerable Populations

Stichwörter der Autor:innen

Barriers to CareCancerGenomicsPrecision Cancer MedicineUnderserved

Autor:innen und Institutionen

  • Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.
  • Department of Research and Evaluation, Patient Advocate Foundation, Hampton, VA.

Förderung

  • Intramural NIH HHS

Zitieren

APA

Cooper, K. E., Abdallah, K. E., Angove, R. S. M., Gallagher, K. D., & Bonham, V. L. (2022). Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine. Ethnicity & Disease, 32(1), 39-48. https://doi.org/10.18865/ed.32.1.39

Vancouver

Cooper KE, Abdallah KE, Angove RSM, Gallagher KD, Bonham VL. Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine. Ethnicity & Disease. 2022;32(1):39-48. doi:10.18865/ed.32.1.39

BibTeX
@article{Cooper2022,
  author = {Cooper, Kayla E and Abdallah, Khadijah E and Angove, Rebekah S M and Gallagher, Kathleen D and Bonham, Vence L},
  title = {Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine},
  journal = {Ethnicity & Disease},
  year = {2022},
  volume = {32},
  number = {1},
  pages = {39--48},
  doi = {10.18865/ed.32.1.39}
}
Kostenlos starten →